Global Periodic Fever Syndromes Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Global Periodic Fever Syndromes Market Segmentation, By Type (Hyperimmunoglobulinemia D Syndrome, Familial Mediterranean Fever, TNF Receptor Associated Periodic Syndrome, Cryopyrin Associated Periodic Syndrome, and Others), Treatment (Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), Anti-TNF Therapy, and Others), Route of Administration (Oral, Injections, Intravitreal, and Others), End-Users (Clinic, Hospital, and Others) - Industry Trends and Forecast to 2032

Periodic Fever Syndromes Market Size

• The global periodic fever syndromes market size was valued at USD 626.20 billion in 2024 and is expected to reach USD 850.43 billion by 2032, at a CAGR of 3.90% during the forecast period
• The market growth is primarily driven by increasing awareness and improved diagnostic capabilities for rare autoinflammatory diseases, coupled with advancements in genetic testing and targeted therapies
• Furthermore, rising prevalence of hereditary periodic fever syndromes, along with growing demand for effective and personalized treatment options, is positioning this market as a critical segment within rare disease therapeutics. These factors collectively propel the expansion of periodic fever syndromes diagnostics and treatment solutions, significantly enhancing market growth

Periodic Fever Syndromes Market Analysis

• Periodic fever syndromes, characterized by recurrent episodes of fever and systemic inflammation, are increasingly recognized as important rare autoinflammatory disorders requiring advanced diagnostic and therapeutic approaches in both clinical and hospital settings due to their complex genetic and inflammatory nature
• The escalating demand for effective diagnostics and targeted treatments is primarily fueled by growing awareness of these rare diseases, advancements in genetic testing technologies, and rising patient diagnosis rates globally
• North America dominates the periodic fever syndromes market with the largest revenue share of 39.5% in 2024, characterized by advanced healthcare infrastructure, widespread availability of genetic testing, and a strong presence of key pharmaceutical players developing innovative biologic therapies
• Asia-Pacific is expected to be the fastest growing region in the periodic fever syndromes market during the forecast period due to improving healthcare access, rising awareness, and increasing adoption of advanced diagnostics and therapies in countries such as China, India, and Japan
• Familial mediterranean fever segment dominates the periodic fever syndromes market with a market share of 44.5% in 2024, driven by its higher prevalence, established treatment protocols, and growing focus on personalized medicine

Report Scope and Periodic Fever Syndromes Market Segmentation 

Periodic Fever Syndromes Market Trends

“Advancements in Genetic Testing and Targeted Biologic Therapies”

• A significant and accelerating trend in the global periodic fever syndromes market is the advancement and increasing adoption of genetic testing technologies and targeted biologic therapies, which are revolutionizing diagnosis and personalized treatment approaches for these rare autoinflammatory disorders

  • For instance, next-generation sequencing (NGS) panels now enable faster and more accurate identification of mutations associated with familial Mediterranean fever (FMF), TNF receptor-associated periodic syndrome (TRAPS), and other related conditions. Similarly, biologics such as canakinumab and anakinra are being increasingly used to manage symptoms and reduce flare-ups

• Genetic testing advancements enable early diagnosis and precise classification of periodic fever syndromes, allowing clinicians to tailor treatments effectively. Targeted biologics work by modulating specific inflammatory pathways, significantly improving patient outcomes and quality of life. Furthermore, ongoing research into novel therapies aims to expand treatment options
• The integration of diagnostic tools with patient management platforms facilitates continuous monitoring and personalized care, helping healthcare providers adjust therapies based on patient response and disease activity. This holistic approach improves disease management and reduces complications
• The demand for innovative diagnostic solutions and targeted treatments is growing rapidly across both developed and emerging markets, as patients and healthcare providers increasingly prioritize accuracy, efficacy, and improved quality of life in disease management

Periodic Fever Syndromes Market Dynamics

Driver

“Increasing Awareness and Advancements in Diagnostics and Targeted Therapies”

• The rising awareness of periodic fever syndromes among healthcare providers and patients, coupled with significant advancements in genetic diagnostics and targeted biologic therapies, is a major driver fueling the growth of the periodic fever syndromes market

  • For instance, in 2024, several leading pharmaceutical companies expanded their pipeline of biologic drugs designed specifically for autoinflammatory conditions, such as canakinumab and anakinra, aimed at improving symptom management and reducing flare-ups. These innovations are expected to accelerate market growth during the forecast period

• As more patients are accurately diagnosed through advanced genetic testing and biomarker identification, demand for effective, personalized treatment options has increased substantially, offering improved disease management over traditional symptom-based therapies
• Furthermore, increasing collaborations between healthcare providers and research organizations are facilitating better patient registries and awareness programs, which contribute to earlier diagnosis and treatment initiation
• The growing adoption of biologics and targeted therapies, combined with improved diagnostic infrastructure, supports enhanced patient outcomes and quality of life, driving the expansion of market opportunities across both developed and emerging regions

Restraint/Challenge

“Limited Awareness and High Treatment Costs”

• Limited awareness of periodic fever syndromes among general practitioners and in some regions poses a significant challenge to timely diagnosis and treatment, often leading to underdiagnosis or misdiagnosis. This lack of awareness can delay patient access to effective therapies, restricting market growth

  • For instance, in many developing countries, insufficient genetic testing facilities and lack of specialized healthcare professionals contribute to delayed or inaccurate diagnosis, hindering treatment uptake

• In addition, the high cost of advanced biologic therapies and long-term treatment regimens presents a major barrier for many patients, especially in regions without adequate healthcare reimbursement or insurance coverage. While some biosimilars and generic options are emerging, the overall expense remains significant
• The complexity of managing these rare diseases, combined with economic challenges faced by patients and healthcare systems, limits widespread adoption of newer therapies, particularly in low- and middle-income countries
• Overcoming these challenges through increased disease awareness programs, improved diagnostic infrastructure, and initiatives to reduce treatment costs will be crucial for expanding access and sustaining market growth globally

Periodic Fever Syndromes Market Scope

The market is segmented on the basis of type, treatment, route of administration, and end-users.

• By Type

On the basis of type, the periodic fever syndromes market is segmented into Hyperimmunoglobulinemia D Syndrome, Familial Mediterranean Fever (FMF), TNF Receptor Associated Periodic Syndrome (TRAPS), Cryopyrin Associated Periodic Syndrome (CAPS), and Others. Familial mediterranean fever held the largest market revenue share of 44.5% in 2024, driven by its higher prevalence in Mediterranean and Middle Eastern populations and well-established treatment protocols.

The TNF Receptor Associated Periodic Syndrome (TRAPS) segments is expected to witness the fastest CAGR from 2025 to 2032, due to increasing diagnosis rates, advances in genetic testing, and the development of targeted biologic therapies for these rarer syndromes. The expanding understanding of the molecular basis of these diseases is fueling demand for personalized treatment approaches across all types

• By Treatment

On the basis of treatment, the market is segmented into non-steroidal anti-inflammatory drugs (NSAIDs), Anti-TNF Therapy, and others. The Anti-TNF therapy segment held the largest revenue share in 2024, supported by its proven efficacy in controlling inflammation and preventing flare-ups, especially in TRAPS patients. NSAIDs maintain significant usage due to their wide availability and affordability for symptom relief in mild cases.

The Others segment, is expected to grow at the fastest CAGR over the forecast period, driven by increasing adoption of precision medicine and improved patient outcomes.

• By Route Of Administration

On the basis of route of administration, the market is segmented into oral, injections, intravitreal, and others. Oral administration segmentation held the largest share in 2024 due to ease of use and patient compliance with NSAIDs and oral biologic therapies where applicable.

Injectable therapies segment is anticipated to witness the fastest growth rate from 2025 to 2032, owing to their increasing role in targeted treatment strategies requiring subcutaneous or intravenous delivery. Intravitreal administration remains a niche segment mostly related to rare inflammatory ocular complications associated with some syndromes.

• By End Users

On the basis of end-users, the market is segmented into clinics, hospitals, and others. Hospitals segment held the largest market revenue share in 2024 due to their advanced diagnostic facilities and capacity to administer complex biologic treatments and monitor patients with severe periodic fever syndromes.

Clinics segment is expected to witness the fastest CAGR from 2025 to 2032, driven by the increasing role of outpatient management and genetic counseling in disease diagnosis and treatment. The rise in specialized autoinflammatory disease clinics globally supports the expansion of this segment.

Periodic Fever Syndromes Market Regional Analysis

• North America dominates the periodic fever syndromes market with the largest revenue share of 39.5% in 2024, driven by advanced healthcare infrastructure, widespread availability of genetic testing, and a strong presence of key pharmaceutical players developing innovative biologic therapies
• Patients and healthcare providers in the region highly value early and accurate diagnosis, as well as access to cutting-edge biologic therapies and comprehensive disease management programs, which contribute to improved patient outcomes
• This widespread adoption is further supported by strong government initiatives, favorable reimbursement policies, and ongoing research investments, establishing North America as a key market for periodic fever syndrome treatments in both clinical and hospital settings

U.S. Periodic Fever Syndromes Market Insight

The U.S. periodic fever syndromes market captured the largest revenue share of 80.5% in 2024 within North America, driven by advanced healthcare infrastructure, widespread access to genetic and molecular diagnostic tools, and increasing awareness of autoinflammatory disorders among clinicians. Patients and healthcare providers prioritize early diagnosis and personalized treatment regimens involving biologics and targeted therapies, contributing to the robust market demand. Moreover, ongoing clinical research and government funding for rare diseases further support market expansion in the U.S.

Europe Periodic Fever Syndromes Market Insight

The Europe periodic fever syndromes market is projected to expand at a significant CAGR throughout the forecast period, fueled by increasing healthcare expenditure, rising prevalence of hereditary autoinflammatory diseases, and improved diagnostic capabilities. Stricter regulatory frameworks and reimbursement policies in countries such as Germany, France, and the U.K. enhance patient access to novel therapies. In addition, the region benefits from established patient advocacy groups raising awareness and driving early diagnosis initiatives.

U.K. Periodic Fever Syndromes Market Insight

The U.K. periodic fever syndromes market is expected to grow at a noteworthy CAGR due to rising awareness of rare autoinflammatory diseases and increased adoption of advanced therapeutics such as anti-TNF agents and IL-1 inhibitors. The National Health Service’s (NHS) focus on rare disease management and access to specialist clinics is boosting diagnosis rates and treatment uptake. Increasing collaboration between research institutions and pharmaceutical companies also propels innovation in the market.

Germany Periodic Fever Syndromes Market Insight

The Germany periodic fever syndromes market is anticipated to expand steadily during the forecast period, supported by robust healthcare infrastructure and a strong focus on genetic research and rare diseases. The country’s healthcare policies favor reimbursement for innovative therapies, encouraging the use of targeted biologics. Growing physician awareness and improved patient screening programs are further driving demand, especially in specialized hospital and clinical settings.

Asia-Pacific Periodic Fever Syndromes Market Insight

The Asia-Pacific periodic fever syndromes market is expected to grow at the fastest CAGR during the forecast period, propelled by increasing healthcare investments, expanding diagnostic capabilities, and rising prevalence of hereditary periodic fever syndromes in countries such as China, Japan, and India. Government initiatives aimed at improving rare disease management and expanding access to specialty healthcare services are supporting market growth. Moreover, improving awareness and availability of biologic treatments are facilitating adoption in the region.

Japan Periodic Fever Syndromes Market Insight

The Japan periodic fever syndromes market is gaining traction due to the country’s well-established healthcare system, high rates of diagnostic testing, and growing focus on rare diseases. The aging population and rising incidence of autoinflammatory conditions contribute to increasing demand for effective therapies. Integration of advanced biologic treatments into clinical practice and government support for rare disease programs are further driving market growth.

India Periodic Fever Syndromes Market Insight

The India periodic fever syndromes market accounted for the largest market revenue share in Asia-Pacific in 2024, attributed to growing awareness of hereditary periodic fever syndromes, increasing healthcare access, and expanding specialty clinics. The rise in availability of affordable diagnostic tests and biologic therapies, along with government initiatives to improve rare disease care, are key factors propelling market growth. In addition, a young population and increasing prevalence of genetic disorders are expected to sustain long-term demand

Periodic Fever Syndromes Market Share

The periodic fever syndromes industry is primarily led by well-established companies, including:

• Novartis AG (Switzerland)
• Regeneron Pharmaceuticals Inc. (U.S.)
• Swedish Orphan Biovitrum AB (Sweden)
• Amgen Inc. (U.S.)
• AbbVie Inc. (U.S.)
• F. Hoffmann-La Roche Ltd (Switzerland)
• Pfizer Inc. (U.S.)
• Amgen Inc. (U.S.)
• Sanofi (France)
• Takeda Pharmaceutical Company Limited (Japan)
• Johnson & Johnson Services, Inc. (U.S.)
• Merck & Co., Inc. (U.S.)
• Revive Therapeutics Ltd. (Canada)
• Kiniksa Pharmaceuticals (Bermuda)
• R-Pharm Group (Russia)
• OLATEC THERAPEUTICS LLC (U.S.)
• XBiotech USA, INC. (U.S.)
• Boehringer Ingelheim International GmbH (Germany)

Latest Developments in Global Periodic Fever Syndromes Market

• In March 2025, Novartis initiated a Phase III clinical trial for Ilaris (canakinumab) targeting Cryopyrin-Associated Periodic Syndromes (CAPS), Familial Mediterranean Fever (FMF), Tumor Necrosis Factor Receptor-Associated Periodic Syndrome (TRAPS), and Hyperimmunoglobulinemia D Syndrome (HIDS). This non-interventional study aims to evaluate the safety and effectiveness of Ilaris in both adult and pediatric patients across multiple centers in Korea
• In February 2025, The U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to Goflikicept (RPH-104), a novel heterodimeric hybrid protein capable of binding with high affinity to human IL-1β and IL-1α, for the treatment of CAPS. This designation is expected to facilitate the drug's development and expedite its review process
• In January 2025, The European Medicines Agency (EMA) included discussions on anti-TNF therapies for TRAPS in its Committee for Medicinal Products for Human Use (CHMP) meeting agenda. The focus was on evaluating the efficacy and safety of these therapies, reflecting the EMA's commitment to addressing rare autoinflammatory conditions
• In December 2024, A study published in the Journal of Rheumatology reported that tocilizumab effectively reduces flares of Hyperimmunoglobulinemia D Syndrome (HIDS) in pediatric patients. The study highlighted the drug's potential in managing this rare autoinflammatory disease, offering a promising treatment option for affected children
• In November 2024, A global patient registry for Periodic Fever Syndromes was established to collect comprehensive data on disease prevalence, genetic markers, and treatment outcomes. This initiative aims to enhance understanding of these rare conditions and support the development of targeted therapies

SKU-47964